Table 1.
Clinical and demographic characteristics
| Variable | Controls (n = 24) | Renal disease (n = 30) | CABG 1–2 hours (n = 8) | CABG 12–24 hours (n = 13) |
|---|---|---|---|---|
|
Male (%) |
46 |
80 |
88 |
85 |
|
Age (years) |
39 ± 12 |
43 ± 24 |
65 ± 8 |
66 ± 10 |
|
Serum albumin (g/l) |
n.a. |
34 (24–35) |
n.a. |
n.a. |
|
Serum creatinine (μmol/l) |
75 (68–83) |
107 (23–147) |
93 (74–116) |
85 (51–102) |
|
eGFR (ml/min/1.73 m2) |
84 (77–108) |
57 (34–65) |
73 (58–95) |
85 (17–128) |
|
Proteinuria (g/d) |
n.a. |
4.5 (1.7-9.4) |
n.a. |
n.a. |
|
Serum β2m (mg/l) |
n.a. |
2.9 (2.2-4.6) |
2.1 (1.6-2.9) |
1.8 (1.3-2.5) |
|
Serum hepcidin-25 (nmol/l) |
4.4 (3.2-5.8) |
3.1 (1.1-5.7) |
4.7 (1.5-7.1) |
14.1 (11.1-17.8) |
|
Urine β2m (nmol/mmol creatinine) |
n.a. |
142 (13–863) |
312 (1528–5239) |
66 (21–86) |
|
Urine hepcidin-25 (nmol/mmol creatinine) |
0.9 (0.4-1.7) |
1.4 (0.3-7.1) |
10.4 (0.8-18.7) |
52.2 (34.0-112.1) |
|
FE of β2m (%) |
n.a. |
5.1 (0.7-39.1) |
14.1 (7.1-20.7) |
2.7 (0.8-3.7) |
|
FE of hepcidin-25 (%) |
1.9 (1.0-3.2) |
8.0 (1.9-20.3) |
21.1 (7.2-23.1) |
33.1 (22.2-52.9) |
| Duration of CPB (min) | - | - | 101 (63–147)# | 106 (92–125)# |
Median (interquartile range), mean ± SD, eGFR = estimated glomerular filtration rate, n.a. = not available, FE = fractional excretion, CABG = coronary artery bypass grafting, CPB = cardiopulmonary bypass, # one patient underwent off-pump CABG.